ALK and non-small cell lung carcinoma: For example, the KEYNOTE‐042 study9 showed that pembrolizumab could improve OS in advanced NSCLC patients with PD‐L1 TPS >1% and without oncogenic EGFR or ALK mutations as compared with chemotherapy.